Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery
Key facts
- Who runs it
- Dong-Xin Wang
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 504 people enrolled
- Started
- 16 Apr 2019
- Ended
- 18 May 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dexmedetomidine
- Placebo
- Record updated
- 27 April 2026
Who can take part
- Age
- 60 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age ≥60 years but <90 years
- Scheduled to undergo cardiac surgery with cardiopulmonary bypass under general anesthesia
- Expected to stay in the intensive care unit (ICU) for at least 1 night after surgery
Who cannot take part
- Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or the snoring, tiredness, observed apnea, high blood pressure-body mass index, age, neck circumference and gender [STOP-Bang] questionnaires ≥3)
- Severe renal dysfunction (requirement of renal replacement therapy) before surgery
- Current treatment with dexmedetomidine or clonidine
- Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis
- Inability to communicate during the preoperative period because of coma, profound dementia or language barrier
- Preoperative sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree atrioventricular block or above without pacemaker
- Patients who meet any of the following criteria will be excluded
- Refuse to participate in the study
- Severe hepatic dysfunction (Child-Pugh class C)
- Presence of delirium (diagnosed by the Confusion Assessment Method [CAM]/CAM for the Intensive Care Unit [CAM-ICU])
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Delirium is an acutely occurred and fluctuating cerebral dysfunction characterized with inattention, altered consciousness, cognitive decline and/or abnormal perception. It is common in the elderly after cardiac surgery and is associated with worse outcomes. Causes leading to delirium are multifactorial but sleep disturbances remains an important one. In previous studies, sedative-dose dexmedetomidine improves sleep quality in ICU patients with mechanical ventilation; and low-dose dexmedetomidine improves sleep quality in postoperative patients without mechanical ventilation. In recent studies of elderly after noncardiac surgery, night-time infusion of low-dose dexmedetomidine reduces delirium and improves 2-year survival. The investigators hypothesize that, for elderly patients after cardiac surgery, night-time infusion of dexmedetomidine may also improve sleep quality, reduce delirium development and improve 2-year survival.
The 2 groups in the trial
- Dexmedetomidine groupTreatment being tested
Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
Treatment: Dexmedetomidine
- Placebo groupPlacebo, for comparison
Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Low-dose Dexmedetomidine on Postoperative Delirium in Patients After Cardiac Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial
- Record updated
- 27 April 2026